{{Rsnum
|rsid=10889160
|Gene=CYP2J2
|Chromosome=1
|position=59896449
|Orientation=minus
|GMAF=0.2351
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(A;A)
|geno2=(A;G)
|geno3=(G;G)
|effect1=
|effect2=
|effect3=
|Gene_s=CYP2J2
}}A study of 858 cases concluded that SNPs in the intron of the [[CYP2J2]] gene were associated with increased risk for [[myocardial infarction]]. [[rs10889160]] had an odds ratio of 1.24, CI: 1.07-1.43, p=0.004.{{PMID|18496133}}
{{ neighbor
| rsid = 11572325
| distance = 419
}}

{{PharmGKB
|RSID=rs10889160
|Name_s=
|Gene_s=CYP2J2
|Feature=
|Evidence=PubMed ID:18496133
|Annotation=The G allele of this intronic SNP is associated with 1.24-fold increased incidence of nonfatal myocardial infarction relative to the A allele. This SNP is not associated with ischemic stroke risk.
|Drugs=
|Drug Classes=
|Diseases=Myocardial Infarction
|Curation Level=Curated
|PharmGKB Accession ID=PA161795933
}}

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs10889160
|overall_frequency_n=27
|overall_frequency_d=126
|overall_frequency=0.214286
|n_genomes=23
|n_genomes_annotated=0
|n_haplomes=26
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}